Tyrosine kinase inhibitors are a new class of anticancer drugs, that are capable of directly interacting with the catalytic site of the target enzyme and thereby inhibiting catalysis. Therapeutically useful tyrosine kinase inhibitors are not specific for a single tyrosine kinase, but rather they are selective against a limited number of tyrosine kinases. The success of imatinib-mesylate (Gleeve...

Novel inhibitors that target the Eph family of transmembrane tyrosine kinase receptors have been optimized and characterized. Some compounds show remarkable receptor selectivity affinity for inhibit growth colon cancer cells where these are expressed active. More information can be found in Research Article by G. Tosato, H. Schwalbe co-workers (DOI: 10.1002/chem.202203967).

People’s lives and health are gravely threatened by non-small-cell lung cancer (NSCLC). Mutations in epidermal growth factor receptor (EGFR), a transmembrane tyrosine kinase, considered one of the causes NSCLC. Tyrosine kinase inhibitors (TKIs) typically used to treat patients with EGFR mutations. In this study, Gefitinib, member first generation TKIs, was an single-point mutation (single mutan...

This review article outlines the current development of emerging treatment strategies for primary central nervous system lymphoma, a rare brain tumor with, thus far, limited therapeutic options. Small molecule targeted tyrosine kinase inhibitors, immunomodulatory agents, and immune checkpoint inhibitors will be discussed. The mechanisms action, results completed clinical studies, ongoing trials...

Response to tyrosine kinase inhibitors at three months is a predictor for long-term outcome in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. We analyzed 456 newly diagnosed chronic myeloid leukemia patients treated with tyrosine kinase inhibitors to determine their outcome based on their response at six months. Forty-four (10%) patients did not achieve major cytogen...

Background: Patients with non-small cell lung cancer (NSCLC) harboring anaplastic lymphoma kinase (ALK) fusions may benefit from ALK-tyrosine inhibitors (ALK-TKIs). However, few studies have analyzed the clinical outcome in patients multiple ALK fusions, including double or triple fusions. Here, our study aimed to analyze impact of on efficacy receiving ALK-TKIs NSCLC patients.

objective(s) inhibitors of p38 map kinase are considered as suitable target in the treatment of inflammatory diseases such as rheumatoid arthritis and bowel inflammatory diseases. the development of 5-alkylthio-1-aryl-2-(4-pyridinyl) triazoles as inhibitors of p38 map kinase is described. these are analogues of 4- pyridinyl imidazole p38 map kinase inhibitor reported by merck research laborator...

Tyrosine kinase inhibitors (TKIs) are the standard of care for patients with metastatic non-small cell lung cancers (NSCLC) harbouring epidermal growth factor receptor mutations (EGFRm). However, role TKIs is not established in management stage III EGFRm disease. We describe real-world practice testing and use NSCLC KINDLE study, a multicentre, multi-country observational non-interventional stu...

Chronic myeloid leukemia (CML) is a myeloproliferative malignancy due to the formation of BCR-ABL fusion gene in chronic leukemia. This condition causes excessive cell proliferation, resulting an increase number leukocytes. Tyrosine Kinase Inhibitor (TKI) first-line therapy that helps reduce percentage patients with study was conducted determine differences hematological profiles (hemoglobin le...